Tirzepatide
Tirzepatide research peptide. Lyophilized powder, ≥99% purity by HPLC. For research use only.
About Tirzepatide
What is Tirzepatide (LY3298176)?
Tirzepatide, research code LY3298176, is a synthetic 39-amino-acid peptide developed by Eli Lilly. It is a dual agonist at the GIP and GLP-1 receptors – the two main incretin receptors – and is sometimes called a 'twincretin'.
Tirzepatide is authorised as a prescription medicine, but the material sold by Virexa Labs is not a medicinal product. It is a research peptide intended solely for in-vitro laboratory research – not for human or veterinary use.
Structure: a GIP-based, lipidated peptide
The sequence is built on the native GIP backbone, modified so that it also activates the GLP-1 receptor. A C20 fatty diacid, attached via a linker, lets the peptide bind to serum albumin. This protects it from rapid clearance and gives it a half-life of about five days in clinical studies.
Its structure, receptor profile and pharmacokinetics are described in detail in the scientific literature, which makes tirzepatide a practical benchmark compound for assay validation.
- Research code: LY3298176
- Class: dual GIP / GLP-1 receptor agonist
- Structure: 39 amino acids, C20 fatty-diacid lipidation
- Reported half-life: about five days (clinical studies)
Research areas
Tirzepatide is investigated in models of glucose homeostasis, insulin secretion, adipose-tissue biology and appetite-related signalling. Typical preclinical questions concern how GIP and GLP-1 receptor activation interact – for example, whether dual agonism behaves differently from GLP-1 agonism alone in cell-based signalling assays or rodent metabolic models.
Because retatrutide (LY3437943) has a similar architecture but adds glucagon-receptor activity, the two are often compared head to head. The clinical SURPASS and SURMOUNT programmes relate to the authorised medicine, not to research reagents.
Handling, reconstitution and storage
Keep the lyophilised vial at −20 °C, dry and away from light; short periods at 2–8 °C are fine. Reconstitute with bacteriostatic water, added slowly along the vial wall, then swirl gently – never shake, as foaming and shear forces can damage peptides. Store the solution at 2–8 °C, use it within about four weeks and avoid freeze–thaw cycles.
Looking to buy Tirzepatide for research? Every batch is tested by HPLC for ≥99% purity and by mass spectrometry for identity, and the COA is shown on this page.
Frequently asked questions
What is Tirzepatide?
Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. We supply it as a lyophilised research peptide.
Is your Tirzepatide a medicine?
No. Our tirzepatide is a research reagent, not a medicinal product, and is not intended for human or veterinary use.
What do I reconstitute Tirzepatide with?
Usually bacteriostatic water, which we also sell. Add it slowly along the wall of the vial and swirl gently – don't shake.
How should Tirzepatide be stored?
Lyophilised at −20 °C, dry and dark (2–8 °C short term). After reconstitution at 2–8 °C, used within about four weeks, avoiding freeze–thaw cycles.
What purity does your Tirzepatide have?
≥99% by HPLC, with identity confirmed by mass spectrometry. The batch COA is available on the product page.